ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 27 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $53,000 | -20.9% | 148,356 | -2.8% | 0.00% | – |
| Q1 2017 | $67,000 | -10.7% | 152,559 | +0.4% | 0.00% | – |
| Q4 2016 | $75,000 | -1.3% | 151,989 | +0.3% | 0.00% | – |
| Q3 2016 | $76,000 | -49.7% | 151,609 | +0.1% | 0.00% | – |
| Q2 2016 | $151,000 | +96.1% | 151,514 | +33.6% | 0.00% | – |
| Q1 2016 | $77,000 | -43.8% | 113,419 | -0.1% | 0.00% | – |
| Q4 2015 | $137,000 | -45.6% | 113,514 | +0.2% | 0.00% | – |
| Q3 2015 | $252,000 | +6.8% | 113,324 | +11.6% | 0.00% | – |
| Q2 2015 | $236,000 | +69.8% | 101,522 | +56.9% | 0.00% | – |
| Q1 2015 | $139,000 | -6.1% | 64,698 | +0.1% | 0.00% | – |
| Q4 2014 | $148,000 | -14.0% | 64,641 | +0.1% | 0.00% | – |
| Q3 2014 | $172,000 | -29.2% | 64,584 | -1.1% | 0.00% | – |
| Q2 2014 | $243,000 | -72.0% | 65,332 | -11.6% | 0.00% | -100.0% |
| Q1 2014 | $868,000 | +101.4% | 73,870 | +42.8% | 0.00% | – |
| Q4 2013 | $431,000 | -13.6% | 51,738 | -3.9% | 0.00% | – |
| Q3 2013 | $499,000 | -1.0% | 53,840 | +4.7% | 0.00% | – |
| Q2 2013 | $504,000 | – | 51,412 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,111,590 | $7,876,000 | 3.50% |
| Abingworth LLP | 603,740 | $2,234,000 | 1.04% |
| BVF INC/IL | 862,069 | $3,216,000 | 0.51% |
| SABBY MANAGEMENT, LLC | 922,562 | $3,441,000 | 0.15% |
| TFS CAPITAL LLC | 360,260 | $1,344,000 | 0.11% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 175,980 | $656,000 | 0.04% |
| Tekla Capital Management LLC | 113,100 | $422,000 | 0.04% |
| Visium Asset Management, LP | 598,443 | $2,232,000 | 0.04% |
| A.R.T. Advisors, LLC | 101,905 | $380,000 | 0.02% |
| B. Riley Wealth Management, Inc. | 6,300 | $23,000 | 0.02% |